[Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothe

Document type:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Editorial Material
Author(s):: Rexer, H; Retz, M; Albers, P
Title:: [Adjuvant study of high-risk muscle invasive urothelial carcinoma : Open-label, multicenter, randomized phase III study with atezolizumab (anti-PD-L1 antibody) as adjuvant therapy compared with observation in patients with high-risk muscle invasive urothe
Journal title abbreviation:: Urologe A
Year:: 2016
Journal volume:: 55
Journal issue:: 11
Pages contribution:: 1491-1493
Language:: de
Fulltext / DOI:: doi:10.1007/s00120-016-0248-5
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/27714413
Print-ISSN:: 0340-2592
TUM Institution:: Urologische Klinik und Poliklinik
BibTeX

Occurrences: